Chojęta Dariusz, Kozioł Małgorzata M, Targońska Sylwia, Smarz-Widelska Iwona
Students Scientific Association at the Chair and Department of Medical Microbiology, Medical University of Lublin, Lublin, Poland.
Chair and Department of Medical Microbiology, Medical University of Lublin, Lublin, Poland.
Kardiochir Torakochirurgia Pol. 2020 Sep;17(3):160-164. doi: 10.5114/kitp.2020.99081. Epub 2020 Sep 23.
Uromodulin (Umod) is a protein produced exclusively in the kidneys, and it is the most abundant protein in human urine. Scientific studies show that it can be a valuable diagnostic tool in monitoring kidney function. Clinical applications of Umod are probably wider. One of them is the role of a biomarker in cardiac surgery-associated acute kidney injury (CSA-AKI). Data from scientific studies indicate that a lower level of Umod in urine prior to surgery is associated with a higher risk of developing CSA-AKI after the procedure. A higher serum Umod level is suspected to be a good prognostic factor in the context of renal healing. It seems that the current state of knowledge supports the protective role of Umod in the course of AKI. Large, multi-center clinical trials would allow for the consolidation of preliminary scientific data and a more accurate understanding of the role of Umod as a CSA-AKI biomarker.
尿调节蛋白（Umod）是一种仅在肾脏中产生的蛋白质，并且是人类尿液中含量最丰富的蛋白质。科学研究表明，它可能是监测肾功能的一种有价值的诊断工具。Umod的临床应用可能更广泛。其中之一是作为生物标志物在心脏手术相关急性肾损伤（CSA-AKI）中的作用。科学研究数据表明，术前尿中Umod水平较低与术后发生CSA-AKI的风险较高相关。在肾脏愈合的情况下，血清Umod水平较高被怀疑是一个良好的预后因素。目前的知识状态似乎支持Umod在急性肾损伤过程中的保护作用。大型多中心临床试验将有助于整合初步科学数据，并更准确地了解Umod作为CSA-AKI生物标志物的作用。
